COMPARISON OF OUTCOMES BETWEEN PATIENTS WITH MYC REARRANGED DLBCL AND DOUBLE/ TRIPLE HIT HIGH‐GRADE B CELL LYMPHOMA: A PAN‐LONDON RETROSPECTIVE REVIEW. (12th June 2019)